Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 96

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1C
Chunk 96
---
727 Equity compensation plans not approved by security holders— — — Total6,719,073 $30.44 4,609,727 

________________________________________

(1)The securities that may be issued are shares of the Company's Common Stock, issuable upon conversion of outstanding stock options.

(2)The securities that remain available for future issuance are issuable pursuant to the 2021 Equity Incentive Plan.

ITEM 13.     CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

The information required by this item is incorporated by reference to the similarly named section of our Proxy Statement for our 2025 Annual Meeting to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2024.

ITEM 14.     PRINCIPAL ACCOUNTING FEES AND SERVICES.

The information required by this item is incorporated by reference to the similarly named section of our Proxy Statement for our 2025 Annual Meeting to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2024.

PART IV

ITEM 15.     EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

(a)(1)    Index to consolidated Financial Statements

The Financial Statements listed in the Index to consolidated Financial Statements are filed as part of this Annual Report on Form 10-K. See Part II, Item 8—Financial Statement and Supplementary Data.

(a)(2)    Financial Statement Schedules

Other financial statement schedules for the years ended December 31, 2024 and 2023 have been omitted since they are either not required, not applicable, or the information is otherwise included in the consolidated financial statements or the notes to consolidated financial statements.

(a)(3)    Exhibits

The Exhibits listed in the accompanying Exhibit Index are attached and incorporated herein by reference and filed as part of this report.

ITEM 16.     FORM 10-K SUMMARY

None.

EXHIBIT INDEXExhibitNumberDescription2.1 †*Agreement and Plan of Merger, dated September 12, 2018, by and between Supernus Pharmaceuticals, Inc., Supernus Merger Sub, Inc. Biscayne Neurotherapeutics, Inc. and Reich Consulting Group, Inc., as amended by Amendment No. 1, dated September 21, 2018 (incorporated by